BM-DCs that express dysfunctional β2-integrin have enhanced tumor rejection capabilities in B16.OVA and B16-F10 melanoma models and higher levels of expression of CD86, Il12, ccr7, and Fscn1, which are indicative of improved co-stimulation and migration capacity. This evidence concerns the gene CD86 and neoplasm.